Australia's most trusted source of pharma news
Monday, 22 July 2019
Lost Your Access?
MA Board meets on election
Vote timing just one matter on table for Wednesday.
Waste, IP in NMP Review
Former MA CEO suggests review have a broad focus.
Aug PBS listings underwhelm
New sizes feature in Hunt's monthly Sunday announcement.
AbbVie's new hope gets nod
Possible successor to Humira given TGA go-ahead.
Hunt pulled into Mundi row
Letter to minister bypasses TGA.
Pharmas striving to keep talent
Hiring experts in bid to minimise staff turnover.
Gilead Aussie exec steps down
Takes $1.5m golden handshake and walks after nine years.
IP shock coming for pharma
Law reform makes some patent and licensing deals vulnerable.
GSK vax exec to lead Seqirus
Woman named as GM to replace Gordon Naylor.
Big change for 60-year-old code
MA's code of conduct will have a different look next time around.
Pricing report flags Netflix deal
One of six new drug funding models highlighted.
PBAC webinar spooks industry
Probe into PSD redactions too soon says MA.
Peripatetic Hunt proved costly
Q1 expenses show increased travel allowance claims.
Narcolepsy spend questioned
DUSC says Nuvigil costing PBS more than expected.
PBS growing economy says RBA
'Increased spending' on PBS boosts consumer spend.
BMS takes CT show on the road
Visiting federal MPs in push for clinical trial reform.
Opiate market battle looms
Dependence options widened by new Mundipharma drug.
Success for Novartis, Sanofi, GSK
FDA and EU regulators make key decisions.
Top of the Hill
Price, transparency and new drugs
The challenges threatening traditional funding models.
Events & Conferences
© 2003 - 2019 Lush Media
Pharma in Focus
Jolly Good Design